JP5924863B2 - Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 - Google Patents

Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 Download PDF

Info

Publication number
JP5924863B2
JP5924863B2 JP2010507601A JP2010507601A JP5924863B2 JP 5924863 B2 JP5924863 B2 JP 5924863B2 JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010507601 A JP2010507601 A JP 2010507601A JP 5924863 B2 JP5924863 B2 JP 5924863B2
Authority
JP
Japan
Prior art keywords
asmase
cells
ceramide
apoptosis
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010507601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526153A5 (enExample
JP2010526153A (ja
Inventor
ロトロ、ジミー
カルスニック、リチャード
パスカリーニ、レナーテ
アラップ、ワディ
Original Assignee
スローン ケタリング インスティテュート フォア キャンサー リサーチ
スローン ケタリング インスティテュート フォア キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン ケタリング インスティテュート フォア キャンサー リサーチ, スローン ケタリング インスティテュート フォア キャンサー リサーチ filed Critical スローン ケタリング インスティテュート フォア キャンサー リサーチ
Publication of JP2010526153A publication Critical patent/JP2010526153A/ja
Publication of JP2010526153A5 publication Critical patent/JP2010526153A5/ja
Application granted granted Critical
Publication of JP5924863B2 publication Critical patent/JP5924863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2010507601A 2007-05-06 2008-05-06 Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 Active JP5924863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91629807P 2007-05-06 2007-05-06
US60/916,298 2007-05-06
PCT/US2008/062789 WO2008137901A2 (en) 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015256345A Division JP6251234B2 (ja) 2007-05-06 2015-12-28 Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法

Publications (3)

Publication Number Publication Date
JP2010526153A JP2010526153A (ja) 2010-07-29
JP2010526153A5 JP2010526153A5 (enExample) 2011-06-23
JP5924863B2 true JP5924863B2 (ja) 2016-05-25

Family

ID=39944232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010507601A Active JP5924863B2 (ja) 2007-05-06 2008-05-06 Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法

Country Status (6)

Country Link
US (6) US8562993B2 (enExample)
EP (1) EP2152287B1 (enExample)
JP (2) JP5924863B2 (enExample)
AU (1) AU2008247368B2 (enExample)
CA (1) CA2686722C (enExample)
WO (1) WO2008137901A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
EP2176665B1 (en) 2007-08-16 2016-03-02 The Royal Institution for the Advancement of Learning / McGill University Tumor cell-derived microvesicles
US20130203081A1 (en) * 2010-04-13 2013-08-08 Janusz Rak Tumor cell-derived microvesicles
EP2854850B1 (en) * 2012-05-25 2021-05-26 Sloan Kettering Institute For Cancer Research Compositions for treating or preventing radiation disease and gi syndrome
EP3177650B1 (en) 2014-08-07 2025-11-05 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
AU2016221305B2 (en) * 2015-02-18 2021-05-27 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP4140492A1 (en) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3612211A4 (en) * 2017-04-17 2021-02-17 Memorial Sloan-Kettering Cancer Center INTESTINAL PROTECTIVE EFFECT OF RIG-I / MAVS AND STING ACTIVATION
WO2020231629A1 (en) * 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
CN112255221A (zh) * 2020-10-16 2021-01-22 航科中投生物技术（北京）有限公司 一种生物防护过滤介质浓度及喷涂效果的比色鉴定方法
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES
EP4313035A4 (en) * 2021-03-23 2025-05-28 Spinogenix, Inc. CERTAIN FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS
WO2025076313A1 (en) * 2023-10-04 2025-04-10 Memorial Sloan-Kettering Cancer Center Combination administration of bone marrow and anti-ceramide antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
WO1997037637A1 (en) 1996-04-04 1997-10-16 Ortho Pharmaceutical Corporation Liposome-based topical vitamin d formulation
WO1998019167A2 (en) * 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
US20030190715A1 (en) * 2000-10-12 2003-10-09 Grosse William M. Novel proteins and nucleic acids encoding same
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
WO2005025489A2 (en) 2003-05-09 2005-03-24 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
KR100565437B1 (ko) 2003-07-31 2006-03-30 중앙대학교 산학협력단 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법
JP2008546647A (ja) * 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−ｃｄ１９抗体治療
US8383095B2 (en) 2006-02-14 2013-02-26 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease

Also Published As

Publication number Publication date
WO2008137901A3 (en) 2008-12-24
US20140112932A1 (en) 2014-04-24
JP6251234B2 (ja) 2017-12-20
EP2152287A2 (en) 2010-02-17
WO2008137901A2 (en) 2008-11-13
US20220354861A1 (en) 2022-11-10
CA2686722C (en) 2017-08-15
WO2008137901A9 (en) 2009-04-30
US11207329B2 (en) 2021-12-28
US12121525B2 (en) 2024-10-22
AU2008247368A1 (en) 2008-11-13
EP2152287B1 (en) 2014-04-02
JP2010526153A (ja) 2010-07-29
US9592238B2 (en) 2017-03-14
CA2686722A1 (en) 2008-11-13
US20100239572A1 (en) 2010-09-23
US8562993B2 (en) 2013-10-22
AU2008247368B2 (en) 2013-10-10
WO2008137901A8 (en) 2009-06-11
US20170273987A1 (en) 2017-09-28
US20190046538A1 (en) 2019-02-14
US20250325559A1 (en) 2025-10-23
EP2152287A4 (en) 2011-06-29
JP2016121154A (ja) 2016-07-07

Similar Documents

Publication Publication Date Title
JP6251234B2 (ja) Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
KR101340699B1 (ko) 인간 모노클로날 항체 인간 ｃｄ１３４（ｏｘ４０） 및이의 제조 및 사용 방법
JP6276818B2 (ja) 特に移植片対宿主病（ＧｖＨＤ）を予防するための抗ＣＤ４抗体
JP2022064935A (ja) Ｇｉ症候群及び移植片対宿主病の治療方法
CN101720232B (zh) 具有修饰的效应器功能的fc受体结合型多肽
HU230768B1 (hu) Aß peptidet kiválasztó humanizált ellenanyagok
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
US8197811B2 (en) Methods of use of sialoadhesin factor-2 antibodies
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
CN109476748A (zh) 用于癌症的治疗和诊断方法
US20140023648A1 (en) Treatment of Osteoarthritis Using IL-20 Antagonists
US20250326831A1 (en) Methods for treating disease using psmp antagonists
KR20250006965A (ko) 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160419

R150 Certificate of patent or registration of utility model

Ref document number: 5924863

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250